RankingsPricing
  1. US-listed companies
  2. Bionano Genomics, Inc.

Bionano Genomics, Inc.BNGO

Market cap
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Net loss-18,496,392-29,815,070-41,106,351-72-133-
Net loss-18,496,392-29,815,070-41,106,351-72-133-232
Depreciation and amortization expense11131014
Finance Lease, Right-of-Use Asset, Amortization---000
Goodwill impairment-----77
Accretion Expense---01-
Finance Lease, Right-of-Use Asset, Amortization---000
Noncash Interest Expense568,483883,26910--
Amortization (accretion) of interest on securities-----1
Net realized loss (gain) on investments-----0-0
Non-cash lease expense---100
Settlement of interest on debt---1--
Deferred Income Tax Expense (Benefit)----62-
Deferred Income Tax Expense (Benefit)----62-
Stock-based compensation112102215
Stock-based compensation112102215
Cost of leased equipment sold to customer---100
Provision for bad debt expense-262,000554,8672-1-
Change in fair value of contingent consideration---00-1
Gain on forgiveness of PPP Loan---2--
Change in fair value of convertible notes payable and option liability------1
Loss on debt extinguishment----1--
Loss on High Trail Agreement------19
Cost of leased equipment sold to customer---100
Contingent consideration cash payment in excess of acquisition-date fair value-----1
Client warranty exchange of fixed asset---1--
Accounts receivable900,1192-2,086,927032
Inventory418,9844416244
Prepaid expenses and other current assets-152,012245,046999,19423-1
Other assets----15
Accounts payable-954,3771-1,809,30972-2
Accrued expenses and contract liabilities-247,402-73,910140-3
Change in fair value of contingent consideration---00-1
Accounts receivable900,1192-2,086,927032
Inventory418,9844416244
Prepaid expenses and other current assets-152,012245,046999,19423-1
Other assets----15
Accounts payable-954,3771-1,809,30972-2
Accrued expenses and contract liabilities-247,402-73,910140-3
Net cash used in operating activities-19,943,847-29-38,314,378-72-125-125
BioDiscovery---49--
Purigen acquisition----31-
Purigen acquisition, net of cash acquired--2---
BioDiscovery acquisition, return of purchase consideration from escrow----1-
BioDiscovery acquisition, return of purchase consideration from escrow----1-
Purigen acquisition, return of purchase consideration from escrow-----0
Purchases of property and equipment---12-
BioDiscovery---49--
Purigen acquisition----31-
Purigen acquisition, net of cash acquired--2---
Sale of property and equipment----0-
Purchases of property and equipment-----2
Construction in process---11-
Sale of property and equipment----0-
Purchases of intangible assets----0-
Construction in process---11-
Payment of initial direct costs on lease---1--
Purchases of intangible assets----0-
Purchase of available for sale securities---31384111
Sale and maturities of available for sale securities----201137
Net cash provided by investing activities-331,716-61,056-2,449,952-2788324
Repayment of term-loan debt711515--
Principal payments of financing lease liability---000
Principal payments of financing lease liability---000
Proceeds from sale of common stock-----58
Proceeds from PPP Loan--2---
Offering expenses on sale of common stock--2211
Proceeds from sale of common stock19204034323-
Employee Stock Purchase Plan, Compensation Expense115,464141,70639,661000
Offering expenses on sale of common stock--2211
Proceeds from Warrant Exercises-860,871291000
Employee Stock Purchase Plan, Compensation Expense115,464141,70639,661000
Proceeds from High Trail Agreement-----80
Proceeds from Warrant Exercises-860,871291000
Payments on convertible notes payable-----9
Net cash provided by financing activities36306233623114
Debt issuance costs related to High Trail Agreement-----5
Contingent consideration milestone payment-----9
Net cash provided by financing activities36306233623114
Effect of exchange rates on cash and cash equivalents and restricted cash-----00
Net increase (decrease) in cash and cash equivalents and restricted cash16788,64421-14-1913
Cash paid for interest700,35311202
Operating Lease, Payments---023
Stock Issued---14--
Contingent Consideration, Noncash----13-
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability---51-
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability---51-
Transfer Of Instruments And Servers To Property And Equipment From Inventory---7711
Transfer Of Instruments And Servers To Property And Equipment From Inventory---7711
Capital Expenditures Incurred but Not yet Paid3,150---00
Capital Expenditures Incurred but Not yet Paid3,150---00
Debt Issuance Costs Incurred but Not yet Paid-----0
Forgiveness of PPP Loan---2--
Conversion Of Notes Payable Into Common Stock, Fair Value-----7
Stock issued for services---0--
Warrant Exercise, Non-cash---0--
Net loss-18,496,392-29,815,070-41,106,351-72-133-
Net loss-18,496,392-29,815,070-41,106,351-72-133-232
Depreciation and amortization expense11131014
Finance Lease, Right-of-Use Asset, Amortization---000
Goodwill impairment-----77
Accretion Expense---01-
Finance Lease, Right-of-Use Asset, Amortization---000
Noncash Interest Expense568,483883,26910--
Amortization (accretion) of interest on securities-----1
Net realized loss (gain) on investments-----0-0
Non-cash lease expense---100
Settlement of interest on debt---1--
Deferred Income Tax Expense (Benefit)----62-
Deferred Income Tax Expense (Benefit)----62-
Stock-based compensation112102215
Stock-based compensation112102215
Cost of leased equipment sold to customer---100
Provision for bad debt expense-262,000554,8672-1-
Change in fair value of contingent consideration---00-1
Gain on forgiveness of PPP Loan---2--
Change in fair value of convertible notes payable and option liability------1
Loss on debt extinguishment----1--
Loss on High Trail Agreement------19
Cost of leased equipment sold to customer---100
Contingent consideration cash payment in excess of acquisition-date fair value-----1
Client warranty exchange of fixed asset---1--
Accounts receivable900,1192-2,086,927032
Inventory418,9844416244
Prepaid expenses and other current assets-152,012245,046999,19423-1
Other assets----15
Accounts payable-954,3771-1,809,30972-2
Accrued expenses and contract liabilities-247,402-73,910140-3
Change in fair value of contingent consideration---00-1
Accounts receivable900,1192-2,086,927032
Inventory418,9844416244
Prepaid expenses and other current assets-152,012245,046999,19423-1
Other assets----15
Accounts payable-954,3771-1,809,30972-2
Accrued expenses and contract liabilities-247,402-73,910140-3
Net cash used in operating activities-19,943,847-29-38,314,378-72-125-125
BioDiscovery---49--
Purigen acquisition----31-
Purigen acquisition, net of cash acquired--2---
BioDiscovery acquisition, return of purchase consideration from escrow----1-
BioDiscovery acquisition, return of purchase consideration from escrow----1-
Purigen acquisition, return of purchase consideration from escrow-----0
Purchases of property and equipment---12-
BioDiscovery---49--
Purigen acquisition----31-
Purigen acquisition, net of cash acquired--2---
Sale of property and equipment----0-
Purchases of property and equipment-----2
Construction in process---11-
Sale of property and equipment----0-
Purchases of intangible assets----0-
Construction in process---11-
Payment of initial direct costs on lease---1--
Purchases of intangible assets----0-
Purchase of available for sale securities---31384111
Sale and maturities of available for sale securities----201137
Net cash provided by investing activities-331,716-61,056-2,449,952-2788324
Repayment of term-loan debt711515--
Principal payments of financing lease liability---000
Principal payments of financing lease liability---000
Proceeds from sale of common stock-----58
Proceeds from PPP Loan--2---
Offering expenses on sale of common stock--2211
Proceeds from sale of common stock19204034323-
Employee Stock Purchase Plan, Compensation Expense115,464141,70639,661000
Offering expenses on sale of common stock--2211
Proceeds from Warrant Exercises-860,871291000
Employee Stock Purchase Plan, Compensation Expense115,464141,70639,661000
Proceeds from High Trail Agreement-----80
Proceeds from Warrant Exercises-860,871291000
Payments on convertible notes payable-----9
Net cash provided by financing activities36306233623114
Debt issuance costs related to High Trail Agreement-----5
Contingent consideration milestone payment-----9
Net cash provided by financing activities36306233623114
Effect of exchange rates on cash and cash equivalents and restricted cash-----00
Net increase (decrease) in cash and cash equivalents and restricted cash16788,64421-14-1913
Cash paid for interest700,35311202
Operating Lease, Payments---023
Stock Issued---14--
Contingent Consideration, Noncash----13-
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability---51-
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability---51-
Transfer Of Instruments And Servers To Property And Equipment From Inventory---7711
Transfer Of Instruments And Servers To Property And Equipment From Inventory---7711
Capital Expenditures Incurred but Not yet Paid3,150---00
Capital Expenditures Incurred but Not yet Paid3,150---00
Debt Issuance Costs Incurred but Not yet Paid-----0
Forgiveness of PPP Loan---2--
Conversion Of Notes Payable Into Common Stock, Fair Value-----7
Stock issued for services---0--
Warrant Exercise, Non-cash---0--